The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Anti-LeY monoclonal antibody (mAb) hu3S193 (Rebmab 100) in patients with advanced platinum resistant/refractory (PRR) ovarian cancer (OC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC).
O. Smaletz
Consultant or Advisory Role - Recepta Biopharma
M. D. P. Diz
No relevant relationships to disclose
C. C. Carmo
No relevant relationships to disclose
J. Sabbaga
No relevant relationships to disclose
G. F. Cunha
No relevant relationships to disclose
S. J. Azevedo
No relevant relationships to disclose
F. C. Maluf
No relevant relationships to disclose
C. H. Barrios
No relevant relationships to disclose
R. L. Costa
Research Funding - Recepta Biopharma
A. G. Fontana
Employment or Leadership Position - Recepta Biopharma
V. A. Alves
Research Funding - Recepta Biopharma
A. M. Moro
Employment or Leadership Position - Recepta Biopharma
A. M. Scott
No relevant relationships to disclose
E. W. Hoffman
Employment or Leadership Position - Ludwig Institute for Cancer Research
Consultant or Advisory Role - Recepta Biopharma (U)
L. J. Old
Employment or Leadership Position - Ludwig Institute for Cancer Research